Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay
Bringing advanced mass spectrometry into routine clinical labs, this automated, standardized solution expands Roche’s diagnostic menu into therapeutic drug monitoring.
Latest news
Roche receives FDA clearance for Elecsys® pTau217 Alzheimer’s test
This blood-based biomarker test identifies Alzheimer’s-related amyloid pathology, advancing assessment across primary and specialty care.
FDA clears cobas® eplex respiratory pathogen panel 3
Offering up to five customizable panel configurations, this flexible syndromic test rapidly and accurately identifies respiratory infections.
Roche expands cancer diagnostic portfolio with new mesothelioma differential test
The VENTANA® BAP1 IHC assay helps pathologists accurately identify mesothelioma and distinguish it from other malignancies, including lung cancer.
Related links
Products
Learn more about our portfolio of lab instruments, systems, assays and more
Documents
More than 800,000 documents available on demand — always up-to-date with 24/7 access